Value investing remains one of the most durable approaches in the stock market, but finding companies that are both cheap and fundamentally sound requires a systematic method. The "Decent Value" screen is designed specifically for that purpose: it filters for stocks with strong valuation scores that still maintain decent ratings in profitability, financial health, and growth. The idea is to avoid the classic value trap—a stock that looks cheap on paper but is cheap for a reason, such as deteriorating business quality or excessive debt. By requiring a minimum floor across multiple fundamental dimensions, the screen aims to surface companies where a low valuation is more likely a temporary market disfavor than a sign of permanent impairment.
A stock that recently emerged from this screening process is Pediatrix Medical Group Inc (NYSE:MD). With a network of roughly 4,400 affiliated physicians and clinicians, Pediatrix provides specialized medical services to women, babies, and children across the continuum of care, from obstetrics and maternal-fetal medicine to neonatology and pediatric subspecialties. The company operates primarily through hospital-based neonatal intensive care units (NICUs) and office-based practices, giving it a steady demand profile tied to essential healthcare needs.
Valuation: A Clear Outlier in the Industry
The most convincing argument for Pediatrix as a value candidate lies in its valuation metrics. ChartMill assigns the company a valuation rating of 8 out of 10, indicating that the stock is priced significantly below what its earnings and cash flows would suggest relative to its peers.
- Price/Earnings (P/E) ratio of 11.95: This places Pediatrix cheaper than 90.20% of companies in the Health Care Providers & Services industry. To put that in perspective, the average P/E for its industry peers is approximately 89.41, and the S&P 500 index trades at a P/E of 26.24.
- Price/Forward Earnings ratio of 10.51: Looking at expected earnings, the stock is cheaper than 89.22% of its industry, and well below the S&P 500 forward average of 21.08.
- Enterprise Value to EBITDA and Price/Free Cash Flow multiples: The company is also cheaper than 82.35% and 92.16% of its industry peers on these respective measures.
For a value investor, these figures suggest the market is applying a significant discount to Pediatrix’s earnings stream. The PEG ratio, which adjusts the P/E for growth expectations, also points to a cheap valuation, reinforcing that the discount is not entirely explained by slower future growth.
Profitability: High Returns That Justify a Closer Look
Value without quality is risky, but Pediatrix scores a solid 7 out of 10 on profitability. The company demonstrates strong capital efficiency that places it well above industry medians.
- Return on Assets (ROA) of 8.42% – outperforms 90.20% of industry peers.
- Return on Equity (ROE) of 19.83% – outperforms 87.25% of peers.
- Return on Invested Capital (ROIC) of 11.22% – outperforms 83.33% of peers.
What stands out is the upward trend: the current ROIC of 11.22% is meaningfully higher than the three-year average of 8.21%, indicating that profitability has been improving. Margin quality also supports this picture, with a profit margin of 9.02% (above 91.18% of peers) and an operating margin of 12.37% that has grown nicely in recent years. For a value investor, strong and improving profitability provides some confidence that the underlying business remains healthy, reducing the risk that the cheap valuation is a trap.
Financial Health: Reasonable but Not Flawless
Pediatrix earns a health rating of 6 out of 10. This is not a standout score, but it passes the screen’s requirement for "decent" health. The company has been actively reducing its share count over both the past one and five years, and its debt-to-asset ratio has improved year-over-year.
On the solvency side:
- Debt-to-FCF ratio of 2.49: This means it would take roughly two and a half years of free cash flow to pay off all debt, a figure that outperforms 72.55% of peers.
- Debt-to-Equity ratio of 0.45: Indicates the company is not excessively leveraged relative to its equity base.
- Altman-Z score of 2.42: This places the company in the "grey zone," suggesting some bankruptcy risk but not an immediate danger. The score is in line with the industry average.
Liquidity metrics are adequate, with a current ratio and quick ratio both at 1.33, indicating the company can comfortably meet short-term obligations. The health rating is not perfect, but for a value-oriented screen, it is sufficient when paired with strong valuation and profitability.
Growth: Modest but Present
The growth rating of 4 out of 10 is the weakest of the five pillars, but it does not disqualify the stock from the screen. Past earnings per share (EPS) growth has been solid, with a 32.10% increase in the last year and a 10.01% compound annual growth rate over several years. Revenue, however, declined by 2.25% in the past year, which explains the moderate score.
Forward estimates show expected revenue growth picking up to an average of 3.87% per year, though EPS growth is forecast to slow to just 0.99% annually. The deceleration in EPS growth is a negative, but the acceleration in revenue suggests the top line may be finding a floor. For a value investor, growth does not need to be explosive—what matters is that the company is not in structural decline. Pediatrix’s growth profile, while moderate, is sufficient to support the valuation thesis, especially given that no dividend is paid (score of 0), meaning all capital is retained for operations and potential reinvestment.
Why This Combination Matters for Value Investors
The Decent Value screen is built on the principle that a low valuation alone is not enough—profitability, health, and growth must provide a supporting foundation. Pediatrix delivers on this: its valuation is among the cheapest in its industry, its profitability metrics are among the best, and its financial health, while not perfect, is adequate. The moderate growth profile, while not exciting, does not undermine the case. For a deeper look at the underlying data and calculations, you can review the full fundamental analysis report for MD.
The risk to watch is the modest Altman-Z score and the declining EPS growth rate, but the combination of low multiples and high returns on capital creates a potential margin of safety that value investors often seek. If the market continues to undervalue Pediatrix relative to its earnings power and asset base, the stock may offer room for price appreciation over time.
Finding Similar Opportunities
Pediatrix is just one result from a broader systematic approach. If this profile aligns with your investment framework, you can run the same Decent Value screen yourself to identify other stocks with strong valuation, decent profitability, reasonable health, and moderate growth. Click here to find more stocks using this screen.
This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Pediatrix Medical Group (NYSE:MD): A Decent Value Stock at a Discount
Value investing remains one of the most durable approaches in the stock market, but finding companies that are both cheap and fundamentally sound requires a systematic method. The "Decent Value" screen is designed specifically for that purpose: it filters for stocks with strong valuation scores that still maintain decent ratings in profitability, financial health, and growth. The idea is to avoid the classic value trap—a stock that looks cheap on paper but is cheap for a reason, such as deteriorating business quality or excessive debt. By requiring a minimum floor across multiple fundamental dimensions, the screen aims to surface companies where a low valuation is more likely a temporary market disfavor than a sign of permanent impairment.
A stock that recently emerged from this screening process is Pediatrix Medical Group Inc (NYSE:MD). With a network of roughly 4,400 affiliated physicians and clinicians, Pediatrix provides specialized medical services to women, babies, and children across the continuum of care, from obstetrics and maternal-fetal medicine to neonatology and pediatric subspecialties. The company operates primarily through hospital-based neonatal intensive care units (NICUs) and office-based practices, giving it a steady demand profile tied to essential healthcare needs.
Valuation: A Clear Outlier in the Industry
The most convincing argument for Pediatrix as a value candidate lies in its valuation metrics. ChartMill assigns the company a valuation rating of 8 out of 10, indicating that the stock is priced significantly below what its earnings and cash flows would suggest relative to its peers.
For a value investor, these figures suggest the market is applying a significant discount to Pediatrix’s earnings stream. The PEG ratio, which adjusts the P/E for growth expectations, also points to a cheap valuation, reinforcing that the discount is not entirely explained by slower future growth.
Profitability: High Returns That Justify a Closer Look
Value without quality is risky, but Pediatrix scores a solid 7 out of 10 on profitability. The company demonstrates strong capital efficiency that places it well above industry medians.
What stands out is the upward trend: the current ROIC of 11.22% is meaningfully higher than the three-year average of 8.21%, indicating that profitability has been improving. Margin quality also supports this picture, with a profit margin of 9.02% (above 91.18% of peers) and an operating margin of 12.37% that has grown nicely in recent years. For a value investor, strong and improving profitability provides some confidence that the underlying business remains healthy, reducing the risk that the cheap valuation is a trap.
Financial Health: Reasonable but Not Flawless
Pediatrix earns a health rating of 6 out of 10. This is not a standout score, but it passes the screen’s requirement for "decent" health. The company has been actively reducing its share count over both the past one and five years, and its debt-to-asset ratio has improved year-over-year.
On the solvency side:
Liquidity metrics are adequate, with a current ratio and quick ratio both at 1.33, indicating the company can comfortably meet short-term obligations. The health rating is not perfect, but for a value-oriented screen, it is sufficient when paired with strong valuation and profitability.
Growth: Modest but Present
The growth rating of 4 out of 10 is the weakest of the five pillars, but it does not disqualify the stock from the screen. Past earnings per share (EPS) growth has been solid, with a 32.10% increase in the last year and a 10.01% compound annual growth rate over several years. Revenue, however, declined by 2.25% in the past year, which explains the moderate score.
Forward estimates show expected revenue growth picking up to an average of 3.87% per year, though EPS growth is forecast to slow to just 0.99% annually. The deceleration in EPS growth is a negative, but the acceleration in revenue suggests the top line may be finding a floor. For a value investor, growth does not need to be explosive—what matters is that the company is not in structural decline. Pediatrix’s growth profile, while moderate, is sufficient to support the valuation thesis, especially given that no dividend is paid (score of 0), meaning all capital is retained for operations and potential reinvestment.
Why This Combination Matters for Value Investors
The Decent Value screen is built on the principle that a low valuation alone is not enough—profitability, health, and growth must provide a supporting foundation. Pediatrix delivers on this: its valuation is among the cheapest in its industry, its profitability metrics are among the best, and its financial health, while not perfect, is adequate. The moderate growth profile, while not exciting, does not undermine the case. For a deeper look at the underlying data and calculations, you can review the full fundamental analysis report for MD.
The risk to watch is the modest Altman-Z score and the declining EPS growth rate, but the combination of low multiples and high returns on capital creates a potential margin of safety that value investors often seek. If the market continues to undervalue Pediatrix relative to its earnings power and asset base, the stock may offer room for price appreciation over time.
Finding Similar Opportunities
Pediatrix is just one result from a broader systematic approach. If this profile aligns with your investment framework, you can run the same Decent Value screen yourself to identify other stocks with strong valuation, decent profitability, reasonable health, and moderate growth. Click here to find more stocks using this screen.
This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Read full article here »